Form 4: Cue Biopharma CDO Granted 50,000 Stock Options

Cue Biopharma's Chief Development Officer, Daniel G. Baker, was granted 50,000 stock options with an exercise price of $0.72, effective September 29, 2025.

Summary

• Daniel G. Baker, Chief Development Officer of Cue Biopharma, Inc., was granted 50,000 stock options.
• The stock options have an exercise price of $0.72 per share.
• The grant date for these options is September 29, 2025.
• The options become fully exercisable on the first anniversary of the grant date, which is September 29, 2026.
• The expiration date for these stock options is September 28, 2035.
• The transaction was not made pursuant to a Rule 10b5-1(c) pre-arranged trading plan.

Sentiment

Score: 5

Explanation: The grant of stock options is a standard compensation practice, but the reporting of a transaction date in the future (September 29, 2025) on a Form 4 filed in November 2025 is highly unusual and could raise questions.

Positives

• The grant of stock options to the Chief Development Officer aligns management's interests with those of shareholders.
• Stock options serve as an incentive for executive retention and performance.

Negatives

• No direct negatives are reported in this Form 4 filing.

Risks

• No specific risks are mentioned in this insider transaction report.

Future Outlook

This insider transaction report indicates a long-term incentive for the Chief Development Officer but does not provide broader forward-looking statements or guidance for the company's operations or financial performance.

Management Comments

• No direct management comments or notable quotes are included in this insider transaction report.

Industry Context

The grant of stock options is a standard practice in the biotechnology industry to compensate and incentivize key executives, aligning their long-term interests with company performance and shareholder value creation.

Comparison to Industry Standards

• Stock option grants are a common component of executive compensation packages across the biotech and pharmaceutical sectors, used to attract and retain talent.
• The exercise price of $0.72 would typically be set at or above the market price on the grant date, a common practice for incentive stock options.

Related Party Transactions

• The grant of 50,000 stock options to Daniel G. Baker, Chief Development Officer, is a related party transaction as part of executive compensation.

Stakeholder Impact

• Shareholders: Potential for increased alignment between executive incentives and shareholder value.
• Employees: Standard executive compensation practices can positively influence morale and retention of key personnel.

Next Steps

• The stock options will become fully exercisable on September 29, 2026, subject to continued employment.

Key Dates

Keywords

Cue Biopharma, CUE, Stock Options, Insider Transaction, Executive Compensation, Daniel G. Baker, Chief Development Officer, Form 4